Degarelix vs Leuprolide
Research Verdict
Degarelix is the stronger research reference for the stated comparison criteria. Both: FDA approved.
Quick Answers
Which is better, Degarelix or Leuprolide?
Degarelix is the stronger research reference for the stated comparison criteria. Both: FDA approved.
What is the key difference between Degarelix and Leuprolide?
Leuprolide requires anti-androgen co-administration during the first 2-4 weeks to mitigate testosterone flare; degarelix does not - this simplifies initial treatment but degarelix requires monthly subcutaneous injection vs. leuprolide depot options lasting 3-6 months.
Evidence Comparison
Both: FDA approved. Leuprolide (Lupron): most-prescribed GnRH agonist globally, approved for prostate cancer, endometriosis, uterine fibroids, central precocious puberty - the broadest indication set. Degarelix: Phase 3 CS21 trial head-to-head vs. leuprolide showing faster castration without flare. Leuprolide has broader evidence; degarelix has the flare-avoidance advantage.
Evidence Context Favoring Degarelix
Prostate cancer requiring immediate castrate testosterone levels without flare risk.
Evidence Context Favoring Leuprolide
Any GnRH analog indication (prostate cancer, endometriosis, precocious puberty) where depot convenience, cost, and extensive physician familiarity matter.
Side-by-Side Snapshot
| Evidence grade | Degarelix: Level A Leuprolide: Level A |
|---|---|
| Research status | Degarelix: FDA Approved Leuprolide: FDA Approved |
| Primary category | Degarelix: Sexual Health Leuprolide: Sexual Health |
| Cited studies | Degarelix: 3 Leuprolide: 3 |